甘草及其主要活性成分甘草酸通过调节CYP2/CYP3A4缓解雷公藤多苷片所致肝损伤的作用机制研究
批准号:
82104480
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
郭秋岩
依托单位:
学科分类:
中药抗炎与免疫药理
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
郭秋岩
中文摘要
雷公藤多苷片(TGT)是中药雷公藤的代表制剂,临床用于治疗类风湿性关节炎(RA)疗效确切,但是其治疗窗口狭窄,易产生药源性肝损伤等副作用。“解毒圣药”甘草及其主要活性成分甘草酸具有确切的肝脏保护作用,与雷公藤配伍可达到减毒效果。围绕“甘草及甘草酸缓解TGT所致肝损伤的药效特点与作用机制”这一关键科学问题,根据申请人前期初步明确的CYP2和CYP3A4同时参与TGT所致肝损伤的发生以及甘草酸的肝脏保护效应机制,本项目拟通过结合细胞热转移分析(CETSA)与CRISPR/CAS9构建靶点敲低/敲除细胞模型的技术,进一步研究甘草及甘草酸调节CYP2和CYP3A4的上、下游靶标,全面阐明其通过调节CYP2/CYP3A4缓解TGT所致肝损伤的分子机制。综上,本项目的成功实施,将促进甘草及其主要活性成分甘草酸的解毒机制研究,指导TGT的临床合理应用,也为其他中药的作用机制研究提供方法学参考。
英文摘要
Tripterysium glycosides tablet (TGT), a representative preparation derived from Chinese herbal medicine Tripterygium wilfordii Hook (TWHF), has been effectively used in the treatment of rheumatoid arthritis. Due to the narrow treatment window, it has high risk to produce drug-induced liver injury and other side effects. Gancao (Glycyrrhizae radix et rhizome) and its major bio-active compound Glycyrrhizic acid (GA) have definite liver protective effect, which has been used to attenuate the side effect of TWHF. Preparatory experiments were preformed and demonstrated that CYP2 and CYP3A4 were found to be involved in both TGT-induced liver injury and the liver protection role of GA. To overcome TGT-induced liver injury, the key is to unravel the pharmacological actions and mechanisms of Gancao and GA. Built upon this, I will apply the state-of-art approaches cell thermal transfer assay (CETSA) and CRISPR/cas9 based target knockdown/ knockout system to comprehensively analyse the upstream and downstream targets of CYP2 and CYP3A4 in this project. Specifically, I aim to systematically reveal the pharmacological actions and molecular mechanisms of Gancao and its major bioactive compound GA in alleviating TGT-induced liver injury by regulating CYP2 / CYP3A4. In conclusion, this project aims to provide the foundation that can guide evidence-based usage of TGT in clinics and hold the promise of accelerating the research and development process of novel drugs derived from Gancao. In addition, it also provides us the opportunity and platform to research the pharmacological actions and mechanisms of other traditional Chinese medicines.
药源性肝损伤是指由药物及其代谢产物所引起的肝损伤,最常见的形式是急性肝损伤,虽然轻度肝损伤可以完全恢复,但严重者可转化为慢性肝损伤甚至导致肝衰竭进而危及生命。甘草酸是甘草的主要活性成分,具有肝脏保护、抗氧化、抗炎、免疫调节等药理活性。雷公藤多苷片治疗类风湿性关节炎的临床疗效确切,但安全窗狭窄易导致药源性肝损伤等副作用,提高雷公藤多苷片的临床用药安全性与合理性是亟待解决的科学问题。本研究选择具有确切肝脏保护作用的甘草及其活性成分甘草酸为研究对象,一方面,基于雷公藤多苷片所致肝损伤明确甘草及其主要活性成分甘草酸缓解雷公藤多苷片所致肝损伤的药效作用特点,并阐明其通过调节CYP2/CYP3A4及其上、下游靶标缓解雷公藤多苷片所致肝损伤的分子机理;另一方面,采用CCl4所致肝纤维化小鼠模型,验证了甘草酸通过参与谷胱甘肽代谢来抑制肝纤维化模型小鼠肝脏中的氧化应激并进一步明确甘草酸靶向AKR7A2蛋白,增强肝脏抗氧化应激能力从而缓解肝纤维化。本项目首次从对CYP2和CYP3A4的调控作用角度,系统性阐明甘草及其主要活性成分甘草酸缓解雷公藤多苷片所致肝损伤的效应机制。首次整合传统药理学、现代组学、化学生物学方法,阐明甘草及其主要活性成分甘草酸缓解雷公藤多苷片所致急性肝损伤的药效作用特点及科学内涵,为雷公藤多苷片的临床安全合理用药提供参考依据;本项目的相关成果有利于促进甘草及其主要活性成分甘草酸的解毒机制研究,指导TGT的临床合理应用,也为其他中药的作用机制研究提供方法学参考。
国内基金
海外基金